Safety and Efficacy of Givinostat for Patients with Muscular Dystrophy: A Systematic Review
Pharmacology · 2025
DOI: 10.1159/000547936 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmacology, 2025. Verfasst von Prasanjit Das und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, All India Institute of Medical Sciences Kalyani, Kalyani, India. Hauptthemen laut MEDLINE: Carbamates, Histone Deacetylase Inhibitors, Muscular Dystrophy, Duchenne, Muscular Dystrophies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Muscular dystrophy (MD) refers to a group of genetic disorders leading to progressive weakness and degeneration of skeletal muscle. Among them, Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the most common types. Histone deacetylase inhibitors (i.e., givinostat) is a recently approved therapy for DMD. In this systematic review, we aimed to evaluate givinostat in MD patients regarding safety and efficacy.
Methods
A systematic review was performed according to the PRISMA guidelines by searching through Medline, Embase, Cochrane Library, and Web of Science. Only randomized control trials comparing givinostat vs. placebo or other therapies are included. The primary outcomes were motor function alteration and histopathologic muscle changes and the secondary outcomes were the adverse reactions.
Results
A total of 188 records were identified, and after screening, two clinical trials met the inclusion criteria. In DMD patients, givinostat significantly slowed disease progression, improving four-stair climb times (p = 0.037) and reducing muscle fat infiltration. In BMD patients, fibrosis progression was not significantly different (p = 0.8282), but MRI showed reduced muscle fat replacement. Common adverse events included diarrhoea, thrombocytopenia, and hypertriglyceridemia, leading to dose reductions, though no new safety signals or treatment-related deaths were observed.
Conclusion
Givinostat seems to be effective in slowing disease progression in DMD but has little benefit in BMD. Its safety profile requires rigorous monitoring. Efficacy difference might be explained by the pathophysiology of the disease and the progression rate. Larger and longer follow-up trials are warranted to confirm longer term benefits and to optimize dosing strategies. Givinostat offers potential as a disease-modifying therapy for DMD but requires further investigation to establish its role in BMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, All India Institute of Medical Sciences Kalyani, Kalyani, India.
- Department of Pharmacology, All India Institute of Medical Sciences Gorakhpur, Gorakhpur, India.
- Department of Pharmacology, All India Institute of Medical Sciences Kalyani, Kalyani, India, kaushik.pharm@aiimskalyani.edu.in.
Zitieren
APA
Das, P., Ojha, B., Das, A., Pathak, B. K., & Mukhopadhyay, K. (2025). Safety and Efficacy of Givinostat for Patients with Muscular Dystrophy: A Systematic Review. Pharmacology. https://doi.org/10.1159/000547936
Vancouver
Das P, Ojha B, Das A, Pathak BK, Mukhopadhyay K. Safety and Efficacy of Givinostat for Patients with Muscular Dystrophy: A Systematic Review. Pharmacology. 2025. doi:10.1159/000547936
BibTeX
@article{Das2025,
author = {Das, Prasanjit and Ojha, Bisweswar and Das, Alapan and Pathak, Bhairav Kumar and Mukhopadhyay, Kaushik},
title = {Safety and Efficacy of Givinostat for Patients with Muscular Dystrophy: A Systematic Review},
journal = {Pharmacology},
year = {2025},
doi = {10.1159/000547936}
}
EUVIMED